A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2017

Conditions

Chronic Schizophrenia

Interventions

DRUG

NW-3509A

Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A

DRUG

Placebo

Patients will be given oral dose of matching Placebo

Trial Locations (5)

Collaborative Neuroscience Network., Garden Grove

Ahana Hospital, Madurai

Hassman Research Institute, Berlin

KHM Hospital, Chennai

Tirthalli National Institute of Mental Health and Neurosciences, Bangalore